Acupuncture for Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis Clinical Trial

— ACUSAR  

Official title:

Acupuncture for Seasonal Allergic Rhinitis (ACUSAR) - A Randomised Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00610584
• Other study ID #: EA1/214/07
• Secondary ID: DFG
• Status: Completed
• Phase: N/A
• First received: January 28, 2008
• Last updated: October 22, 2012
• Start date: April 2008
• Est. completion date: April 2011

Study information

• Verified date: October 2012
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

Acupuncture is widely use by patients with seasonal allergic rhinitis (SAR), although there is only limited evidence of its effectiveness. The aim of this three armed randomised controlled multicentre trial is to investigate the efficacy of acupuncture plus rescue medication vs. minimal (sham) acupuncture plus rescue medication vs. (b) rescue medication alone in the treatment of seasonal allergic rhinitis.

Description:

Acupuncture is widely use by patients with seasonal allergic rhinitis (SAR), although there is only limited evidence of its effectiveness. The aims of this 3-armed, randomised controlled trial are to investigate whether acupuncture plus rescue medication is non-inferior (closed testing procedure: in case of success in non-inferiority: test of superiority) to minimal acupuncture plus rescue medication in the treatment of SAR (closed testing procedure: closed testing procedure: in case of success in non-inferiority: test of superiority), and whether acupuncture plus rescue medication is non-inferior to rescue medication alone consisting only of oral antihistamines for this indication. The trial interventions will be performed in approximately 40 outpatient centres in Germany. In total, 400 patients with SAR will be randomised to one of three groups: acupuncture plus rescue medication, minimal acupuncture (i.e. superficial needling at non-acupuncture points) plus rescue medication, or rescue medication only. Rescue medication will consist of oral antihistamines. Acupuncture and minimal acupuncture will be administered by physicians specialised in acupuncture and will consist of 12 sessions per patient in the first 8 weeks. Patients in the rescue medication group will receive 12 sessions of acupuncture after 8 weeks. The primary outcome measures will be the mean of Rhinitis Quality of Life Questionnaire score (RQLQ scores between weeks 6 and 8 of the first year (adjusted for baseline values) and the Rescue Medication Score (RMS) between weeks 6 and 8 of the first year (adjusted for baseline values).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 422
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years to 45 Years

Eligibility

Inclusion Criteria:

• Female or male patients (aged 16-45 years) with seasonal allergic rhinitis, clinically positive and test positive (skin-prick test and/or RAST) to grass and birch pollen

• Patients with >2 years of moderate to severe SAR

• Positive skin-prick test and/or RAST (at least class 2) results

• Visual analogue scale >40mm and <80 mm for SAR symptoms during the past year

• Patients must be able to complete a diary for self-evaluation of symptoms and recording use of anti-symptomatic medication

• Use of, or indication for, oral antihistamines as anti-allergic medication

• Written informed consent

Exclusion Criteria:

• Perennial SAR or other types of chronic rhinitis

• Allergic asthma and/or moderate to severe atopic dermatitis

• Active tuberculosis

• Autoimmune disorders

• Severe chronic inflammatory diseases

• History of anaphylactic reactions

• Hypersensitivity to Rescue medication or related drugs used in study related drugs

• Specific immunotherapy >3 years

• Simultaneous participation in other clinical trials

• Serious acute or chronic organic disease or mental disorder

• Pregnancy or breast feeding

• Allergy desensitisation therapy (current, during the past two years, or planned in the next two years)

• Blood coagulation disorder and/or current use of anticoagulants

• Previous acupuncture treatment for SAR

• Any Complementary and alternative medicine treatment at the moment, in the last three months or planned in the next two years

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Rhinitis
• Rhinitis, Allergic, Seasonal
• Seasonal Allergic Rhinitis

Intervention

Procedure:
• acupuncture
arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
• minimal (sham)acupuncture
arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))

Drug:
• cetirizine dihydrochloride (rescue medication)
arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone

Locations

Country	Name	City	State
Germany	Charité - Institute for Social Medicine	Berlin

Sponsors (2)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany	German Research Foundation

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rhinitis Quality of Life Questionnaire score (RQLQ scores between weeks 6 and 8 of the first year (adjusted for baseline values) and the Rescue Medication Score between weeks 6 and 8 of the first year (adjusted for baseline values).		Weeks 6 and 8 of the first year (adjusted for baseline values).	No
Secondary	Quality of life (SF-36), responder rate (RQLQ score of 0.5 or more), global evaluation of treatment success, VAS (0-100 mm) overall symptom severity and nasal, eye, pharyngeal and common symptoms, safety, patients constitution, health economic analyses.		Baseline, 8 weeks and 16 weeks in the first year and baseline and week 8 in the second year	Yes